Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade has reshaped immuno-oncology, with antibodies establishing benchmarks for survival and durability of response across multiple tumor types. This evidence concerns the gene CD274 and neoplasm.